Prescribing information

 

This page/content is for Great Britain Healthcare professionals only. If you require information for Northern Ireland please refer to the Northern Ireland PI

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

PIQRAY® is given in combination with fulvestrant.1

Dosing and administration1

Dosing and administration dosing guide chart

Continue treatment until disease progression or until unacceptable toxicity occurs.

*Tablets should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked, or otherwise not intact.

Accounting for missed PIQRAY® doses1

  • If a dose is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped for that day. The next day, PIQRAY® should be taken at its usual time
  • If the patient vomits after taking the dose, the patient should not take an additional dose on that day, and should resume the usual dosing schedule the next day at the usual time

Certain AEs may require dose modifications1

Image detailing dose modifications

 

Thumbnail of PIQRAY Management Guide document

THERAPY MANAGEMENT GUIDE

Please see the therapy management guide for more details on dosing and administration.

View resources 

 

The blister pack is designed to help patients stay on track with treatment1

Dosing table. The recommended starting dose of PIQRAY: 300 mg daily + Fulvestrant recommended dose 500 mg

 

AE, adverse event.

Reference     

  1. PIQRAY® (alpelisib) Summary of Product Characteristics. Novartis Pharma; December 2021.
Rate this content: 
No votes yet
UK | April 2022 | 186029
×

Ask Speakers

×

Medical Information Request

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

 

 

 

 

 

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]